Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP glucuronosyltransferase family 2 member A1 (UGT2A1)
- Target
- UGT2A1
- Molecular classification
- Enzyme, UDP-glucuronosyltransferase family, Glycosyltransferase
01
Overview
UDP glucuronosyltransferase family 2 member A1 (UGT2A1) is a membrane-bound enzyme expressed primarily in the olfactory neuroepithelium and responsible for the glucuronidation and detoxification of a wide variety of endogenous and exogenous substances, including steroid hormones, bile acids, and odorant molecules. Through glucuronidation, UGT2A1 increases the solubility of lipophilic compounds, enabling their excretion via urine or bile. The gene shares structural similarities with other UGT family members and functions in both drug metabolism and olfactory signal termination. Variations in UGT2A1 are linked to metabolic syndromes, drug response variability, and loss of smell, especially in the context of COVID-19[3][4].
- Other names
- UDP-glucuronosyltransferase 2A1UD2A1UGT2A1_HUMAN
02
Mechanism of action
Glucuronidation (attachment of glucuronic acid to increase solubility and facilitate excretion)[3]
03
Biological functions
DetoxificationDrug metabolismXenobiotic metabolismSteroid hormone metabolismBile acid conjugationOlfaction (unique to olfactory neuroepithelium[3][4])
04
Disease associations
Loss of smell (anosmia), especially noted in COVID-19[3][4]Crigler-Najjar syndrome, Type IOther drug metabolism disorders
05
Safety considerations
Genetic variations may impact drug efficacy and toxicity[3]Possible impact on sense of smell – relevant in respiratory or neurologic disorders (notably COVID-19-linked anosmia)[3][4]
06
Interacting drugs
Various steroid hormones (testosterone, estradiol)[3]
1 more in the full profile.
07
Biomarkers
Polymorphisms in UGT2A1 associated with altered drug metabolism and olfactory function[3][4]
Beyond the preview
Go deeper on UDP glucuronosyltransferase family 2 member A1 (UGT2A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UDP glucuronosyltransferase family 2 member A1 (UGT2A1).